Cytox, Affymetrix Forge Strategic Partnership to Develop Alzheimer’s Genetic Assay

Cytox Limited and Affymetrix are partnering to develop a blood-based genetic assay for use in diagnosing and making prognoses on Alzheimer’s disease and mild cognitive impairment.

By using a customized genetic variation panel, the companies may be able to evaluate a patient’s risk for developing these conditions, says Dr. Richard Pither, CEO of Cytox. The company’s Axiom genotyping platform will be used in the assay’s development.

Cytox, a UK-based firm, develops tests for dementia and cognitive decline.

Santa Clara, Calif.-based Affymetrix designs products for biological systems analysis at the cellular, protein and genetic level. The company has sales and distribution arms worldwide. — Jason Scott